Packaging PBI's Sample Preparation System With Sage-N's
Software Tools Will Allow Mass Spectrometry Laboratories
Better Access and Support to These Enabling Technologies
SOUTH EASTON, Mass. and MILPITAS, Calif., March 19, 2012
(GLOBE NEWSWIRE) - Pressure BioSciences, Inc. (Nasdaq:
PBIO) ("PBI" and the "Company"), a leading sample
preparation tools company for the research market and
Sage-N Research, Inc. ("Sage-N"), a world leader in
computational proteomics, today announced a collaboration
to develop software applications on Sage-N's SORCERER™
Integrated Data Appliance platform. The new software will
be designed to work with PBI's patented and enabling
pressure cycling technology ("PCT") system, a novel
technology platform that is used to extract, among other
biomolecules, integral cell membrane and other proteins for
subsequent mass spectrometry analysis.
Integral cell membrane proteins are of significant clinical
importance due to their roles in cell signal transduction
in cancer, membrane transport disorders like Crohn's
disease, pathogen invasion such as HIV, and their roles in
other diseases and disorders. Unfortunately, integral cell
membrane proteins are traditionally very difficult to
extract. In some cases, harsh chemicals are used in the
extraction process, causing such severe protein degradation
that subsequent proteomic analysis is compromised.
PBI's PCT Platform uses rapid cycles of low and ultra-high
pressure to safely and effectively extract proteins from
samples (including cell membranes) that are suitable for
analysis by analytical methods such as mass spectrometry.
The PCT Platform also provides a high level of
automation, speed, and reproducibility in the enzymatic
breakdown of proteins. This allows the PCT-enhanced
digestion to be completed in under an hour, compared to the
standard four to twelve hours.
Richard T. Schumacher, President and CEO of PBI, said: "We
plan to seamlessly integrate PBI's front-end PCT Sample
Preparation System (instruments and consumables) with
Sage-N's SORCERER back-end data reduction software. We
expect to offer this bundled platform as an option to
stand-alone sample preparation and data reduction methods
used currently by the mass spectrometry laboratory. We
believe that by bundling these enabling platforms, we will
be offering a higher quality, more efficient, and less
costly solution than they currently have for sample
preparation and data reduction. Since the companies
now target an identical market - the mass spectrometry
laboratory - we expect to share a number of marketing and
selling programs directed at this market going
forward. Overall, we believe our new co-marketing
program will reduce costs and increase sales for both PBI
and Sage-N before the end of 2012."
"Mass spectrometry proteomics continues to evolve from a
general-purpose protein identification technology to
specialized applications, such as characterization of
membrane proteins and detecting novel pathogens," noted
David Chiang, Chairman of Sage-N Research. "Our SORCERER
platform continues to evolve to meet the ever expanding IT
needs of mass spectrometry labs by providing advanced
companion tools for these applications."
Sage-N Research's SORCERER Integrated Data Appliance
platform provides complementary software applications that
are customized for each particular sample preparation
chemistry. This results in a semi-automated system for
membrane and other protein analysis that can use any modern
tandem mass spectrometer and liquid chromatography system.
About Sage-N Research, Inc.
Sage-N Research, Inc. is a world leader in supplying
Integrated Data Appliances (IDAs) for proteomics research.
The industry-leading SORCERER™ IDAs are plug-and-play
productivity systems used by leading life science
researchers worldwide to rapidly and accurately identify
proteins and protein modifications in biological samples
using mass spectrometry data. Founded in 2002, the company
is a privately held corporation headquartered in Silicon
Valley in California. Through strategic collaborations with
leading scientists and companies, Sage-N Research advances
the state of the art in ease-of-use applications and
technology to enable world-changing discoveries in biology
and medicine.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (Nasdaq:
PBIO) is focused on the development, marketing, and
sale of proprietary laboratory instrumentation and
associated consumables based on Pressure Cycling Technology
("PCT"). PCT is a patented, enabling technology
platform with multiple applications in the estimated $6
billion life sciences sample preparation market. PCT uses
cycles of hydrostatic pressure between ambient and
ultra-high levels to control bio-molecular
interactions. PBI currently focuses its efforts on the
development and sale of PCT-enhanced sample preparation
systems (instruments and consumables) for forensics,
biomarker discovery, bio-therapeutics characterization,
vaccine development, soil and plant biology, histology, and
counter-bioterror applications.
Forward-Looking Statements
Statements contained in this press release regarding the
Company's intentions, hopes, beliefs, expectations, or
predictions of the future are "forward-looking" statements
within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, without
limitation, statements regarding the advantages of the
Company's PCT Sample Preparation System ("PCT SPS"), the
collaboration between PBI and Sage-N Research, and the
goals and expected results of the collaboration, including
the seamless integration of the platforms, the advantages
of the integration of Sage-N's software with the Company's
PCT SPS to the mass spectrometry customer, and reduced
costs and increased sales before the end of
2012. These statements are based upon the Company's
current expectations, forecasts, and assumptions that are
subject to risks, uncertainties, and other factors that
could cause actual outcomes and results to differ
materially from those indicated by these forward-looking
statements. These risks, uncertainties, and other factors
include, but are not limited to: due to unanticipated
technical or scientific difficulties or the failure of the
proteomics community to acknowledge the advantages of the
PCT Platform, the Company's collaboration with Sage-N
Research may not achieve the results anticipated by the
Company; possible difficulties or delays in the
implementation of the Company's strategies that may
adversely affect the Company's continued commercialization
of its PCT-based product line; changes in customer's needs
and technological innovations; the Company's sales force
may not be successful in selling the Company's PCT product
line because scientists may not perceive the advantages of
PCT over other sample preparation methods; the Company may
not be successful in raising additional capital necessary
on acceptable terms, if at all, to fund the Company's
operations beyond April 2012; and if the Company fails to
achieve its plan to regain compliance with the NASDAQ
Listing Rules for minimum stockholders' equity and the
minimum bid price of $1.00 per share, the Company's common
stock will be delisted from The NASDAQ Capital Market,
which could impact the Company's ability to raise
capital. Additional risks and uncertainties that could
cause actual results to differ materially from those
indicated by these forward-looking statements are discussed
under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2011,
and other reports filed by the Company from time to time
with the SEC. The Company undertakes no obligation to
update any of the information included in this release,
except as otherwise required by law.
PBI filed a registration statement (including a prospectus)
with the SEC for an offering to which this communication
may relate. Before you invest, you should read the
prospectus in that registration statement for the offering
and other documents PBI has filed with the SEC for more
complete information about PBI and the offering. You may
get these documents for free by visiting EDGAR on the SEC
Web site at
www.sec.gov. Alternatively, PBI can arrange to send you
the prospectus, when available, upon request.
For more information about Sage-N Research, Inc. please
visit
www.SageNResearch.com or e-mail
info@SageNResearch.com. For further information on
Pressure BioSciences, please visit:
www.pressurebiosciences.com or
http://bit.ly/wmA5X5 or email
info@pressurebiosciences.com.
Recommend:
